US 12,070,570 B2
Injectables
Steven Gill, Leeds (GB)
Assigned to Safe IV Ltd., Manchester (GB)
Appl. No. 15/569,553
Filed by Safe IV Ltd., Manchester (GB)
PCT Filed Apr. 29, 2016, PCT No. PCT/GB2016/051251
§ 371(c)(1), (2) Date Oct. 26, 2017,
PCT Pub. No. WO2016/174471, PCT Pub. Date Nov. 3, 2016.
Claims priority of application No. 1507395 (GB), filed on Apr. 30, 2015.
Prior Publication US 2018/0250467 A1, Sep. 6, 2018
Int. Cl. A61M 5/14 (2006.01); A61M 5/00 (2006.01); A61M 5/168 (2006.01); A61M 39/16 (2006.01); A61M 25/00 (2006.01)
CPC A61M 5/14 (2013.01) [A61M 5/007 (2013.01); A61M 5/16831 (2013.01); A61M 39/16 (2013.01); A61M 2005/1403 (2013.01); A61M 2025/0019 (2013.01); A61M 2205/583 (2013.01); A61M 2205/584 (2013.01)] 14 Claims
 
1. A method of administering intravenously a drug product to a human subject in need thereof, the method comprising:
administering the drug product from a first syringe, a first syringe driver, or a first gravity driven drip to the human subject via an intravenous access device configured for repeated use with access to the human subject's vasculature over a period of time; and
following the administration of the drug product and to enable further use of the intravenous access device, passing a pharmaceutically acceptable coloured liquid from a second syringe, a second syringe driver, or a second gravity driven drip through the intravenous access device, wherein a sufficient amount of the pharmaceutically acceptable coloured liquid remains in the intravenous access device to provide a positive visual indication to medical staff elsewhere to a location where the drug was administered that the pharmaceutically acceptable coloured liquid has passed through the intravenous access device and the drug product has been flushed from the intravenous access device and administered to the human subject; wherein the pharmaceutically acceptable coloured liquid does not comprise a drug product, and wherein the administered drug product is a muscle relaxant.